This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Jyothi Nagajyothi, Ph.D. and her laboratory at the Hackensack Meridian Center for Discovery and Innovation (CDI) have identified what may be the main mechanism for how chronic Chagas disease, a parasitic infection affecting millions of people worldwide, can cause irreversible and potentially fatal heart damage.
This was sent by an undergraduate (not yet in medical school, but applying now) who works as an ED technician (records all EKGs, helps with procedures, takes vital signs) and who reads this blog regularly. Edited by Smith He also sent me this great case. A 63 year old man with a history of hypertension, hyperlipidemia, prediabetes, and a family history of CAD developed chest pain, shortness of breath, and diaphoresis after consuming a large meal at noon.
Statement Highlights: More than 40% of adults in the United States live with obesity, and the percentage of people living with obesity continues to increase dramatically. While experts have learned a great deal about the causes of obesity and.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
(MedPage Today) -- LONG BEACH, Calif. -- Both sparsentan (Filspari) and irbesartan were associated with significantly slower estimated glomerular filtration rate (eGFR) decline compared with standard of care in patients with immunoglobulin A.
Endovascular treatment for acute ischemic stroke patients beyond six hours from onset is still effective, according to a collaborative study conducted by the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) and Queen Mary Hospital (QMH). The study, conducted over five years, found that over 30% of patients who received endovascular treatment had a good clinical outcome even after six hours of the onset of symptoms.
Endovascular treatment for acute ischemic stroke patients beyond six hours from onset is still effective, according to a collaborative study conducted by the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) and Queen Mary Hospital (QMH). The study, conducted over five years, found that over 30% of patients who received endovascular treatment had a good clinical outcome even after six hours of the onset of symptoms.
Nature Reviews Cardiology, Published online: 21 May 2024; doi:10.1038/s41569-024-01041-x A study in Nature describes a single-cell-type strategy for vascular cell therapies that involves the artificial transplantation of mitochondria to endothelial cells, which promotes mitophagy and facilitates the formation of functional vessels in ischaemic tissue without the need for mesenchymal stromal cell support.
milla1cf Mon, 05/20/2024 - 08:00 May 20, 2024 — Ochsner Medical Center - Baton Rouge has earned The Joint Commission’s Gold Seal of Approval and the American Stroke Association’s Heart-Check mark for Acute Stroke Ready Certification. The designation means OMC-Baton Rouge meets The Joint Commission's designation for readiness to treat patients who experience severe stroke.
(MedPage Today) -- BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study showed. In terms of safety.
This slide highlights one of the most important studies in cardiovascular medicine. Let’s break it down. In simple terms it shows that if you get the basics right when you are young your future risk of heart disease is massively reduced. If you get 7 core factors right your risk of dying from heart disease over a 32 year time frame drops by 93%.
Black men face significantly worse health outcomes in the US. Henry explains why the clinician needs to focus on building more authentic trust in their interactions.
Circulation, Ahead of Print. Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovascular disease. Over the past decade, obesity science has evolved to improve knowledge of its multifactorial causes, identifying important biological causes and sociological determinants of obesity.
Dolinger reviews findings from his research presented at DDW about the use of intestinal ultrasound response for predicting endoscopic outcomes in children with UC.
The following are key points to remember from a state-of-the-art review on transcatheter-based interventions for tetralogy of Fallot (TOF) across all age groups:
Video 8 in 8 Series: Latin Heart Rounds on Mitral Annular Disjunction kchalko Mon, 05/20/2024 - 08:24 In this 8x8 video (presented in Spanish), Dr. Juan Crestanello, chief of cardiac surgery at Mayo Clinic in Rochester, MN, discusses annular disjunction of the mitral valve, its medical and surgical implications, and also the operative techniques used to deal with this anatomical feature.
Are there differences between empagliflozin and dapagliflozin for the composite outcome of all-cause mortality and hospitalization in patients with heart failure (HF)?
Damas explains key findings from her pilot study exploring intervals of a low-calorie plant-based diet as adjunctive therapy to medication in patients with ulcerative colitis.
The phase 3 QUASAR Maintenace study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.
Does apolipoprotein B (apoB) have a utility in atherosclerotic cardiovascular disease (ASCVD) or are low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), and triglycerides sufficient for routine cardiovascular (CV) care?
A multidisciplinary care team (MDT) must balance the risks and benefits of transvenous lead extraction (TLE) vs. entrapping leads in patients with preexisting leads from cardiac implantable electronic device (CIED) being considered for orthotopic transcatheter tricuspid valve replacement (TTVR), which accounts for roughly 35% of the TTVR population, according to a JACC State-of-the-Art Review, published May 13.
(MedPage Today) -- BOSTON -- In deciding on anticoagulation with apixaban (Eliquis) for patients with device-detected, subclinical atrial fibrillation (SCAF), one key number appeared to distinguish those for whom the benefit would outweigh the.
Several abstracts at Heart Rhythm 2024, held May 16-19 in Boston, MA, featured data from the NCDR suite of registries. Research covered topics such as outcomes for pediatric subcutaneous ICD implantation; procedural success rates and risk factors associated with catheter ablation for atrial tachyarrhythmias; comparing echocardiographic guidance during left atrial appendage occlusion (LAAO); and atrial fibrillation (AFib) ablation in patients with heart failure with reduced ejection fraction (HFr
These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug’s effect on individuals with IPF.
In this episode, host Andrea Price MS, AACC brings together Jamie Jackson, PhD, and David Harrison, MD, to discuss screening for psychological distress (e.g., PHQ-4) and when to refer patients for further evaluation. The importance of identifying psychological distress in cardiovascular medicine is highlighted.
Beth Browning, PA-C, LPC, provides advice for busy primary care providers to efficiently incorporate timely and treatment-initiating depression screening.
The U.S. Food and Drug Administration (FDA) announced on May 15 that Abbott is recalling the HeartMate 3 Left Ventricular Assist System (LVAS) implant kit due to risk of blood leakage or air entering the seal interface between the left ventricular assist device inflow cannula and the apical cuff.
James R. Kilgore, DMSc, PhD, PA-C, discusses a new primary care screening tool for cognitive decline, plus lifestyle interventions that may complement drugs.
Early-career interventional cardiologists are performing PCI procedures on patients with more acute presentations and higher predicted risk of mortality and bleeding than their more experienced counterparts, which are associated with modestly worse outcomes, according to a study published May 13 in JACC.
For patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage, andexanet alfa, which reverses the effects of factor Xa inhibitors, results in better control of hematoma expansion than usual care, according to a study published in the New England Journal of Medicine.
Rezaie describes recent trends in GLP-1RA prescription patterns from his population-based research presented at DDW, highlighting increases in off-label use.
In patients with device-detected atrial fibrillation and a prior stroke, oral anticoagulation increases bleeding without a clear reduction in stroke. This finding was presented by Prof. Paulus Kirchhof, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, in a late-breaking clinical trials session at the annual congress of the American Heart Rhythm Society (HRS 2024) held in Boston, U.S., May 16–19.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content